Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Island Pharmaceuticals Ltd ( (AU:ILA) ) just unveiled an update.
Island Pharmaceuticals Ltd has completed an additional submission to the FDA as part of its ongoing efforts to optimize the development program for its antiviral drug, Galidesivir. This submission follows the FDA’s confirmation that Galidesivir is eligible for the Animal Rule pathway, a significant step that reduces regulatory risk and advances the drug’s development for Marburg virus. The company anticipates a response from the FDA by early January 2026, which will guide the finalization of their study design and facilitate the commencement of a Marburg study in the first quarter of 2026.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian company focused on developing antiviral drugs to address urgent viral diseases, public health, or biosecurity threats. The company is pursuing a dual development strategy with its assets, ISLA-101 and Galidesivir, targeting diseases such as dengue fever and a range of RNA viruses including Ebola, Marburg, and Zika.
Average Trading Volume: 793,312
Technical Sentiment Signal: Buy
Current Market Cap: A$138.8M
See more insights into ILA stock on TipRanks’ Stock Analysis page.